Projects and Grants per year
Grants and Contracts Details
Description
Apolipoprotein A-I (ApoA-I) is the major protein of high-density lipoprotein (HDL). It is essential for HDL
formation and the efflux of cholesterol from macrophage foam cells found in atherosclerotic plaques.
Antibodies targeting this protein have been identified in obese patients and patients with autoimmune
disorders. While the antibodies are correlated with an increased risk for major adverse cardiac events, the
exact role of these antibodies in disease is unclear. Post-translational modifications of ApoA-I have been
observed in patients with cardiovascular disease and these modifications have been shown to break
tolerance in autoimmune disorders, suggesting a causative role in cardiovascular disease. However, these
post- translational modifications do alter HDL function and may be protective by eliminating defective ApoA-I
and HDL from circulation. The lack of appropriate animal models, however, prevents the elucidation of their
role in disease. We hypothesize that an immunostimulatory formulation containing post-translationally
modified peptide epitopes from ApoA-I will break tolerance in mice and generate a more efficient mouse
model to study the role of antibodies in disease progression. Based on this hypothesis, we propose two aims
to investigate the role of antibodies in cardiovascular disease.
In AIM 1, we will measure the antibody titers directed toward ApoA-I in mice and monkeys with
atherosclerotic plaques. We will correlate the antibody response to atherosclerotic plaque progression and
dietary fat intake. In AIM 2 we will immunize mice using a multicomponent immunostimulatory formulation
containing post-translationally modified peptide epitopes derived from ApoA-I and an adjuvant. This
formulation is designed to break tolerance and induce a robust immune response toward self. The Aims
proposed in this application will allow us to study the role of these autoantibodies in mice with the long term
goal of developing therapeutics aimed at preventing and treating cardiovascular disease.
Status | Finished |
---|---|
Effective start/end date | 9/8/08 → 7/31/16 |
Funding
- National Institute of General Medical Sciences
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Projects
- 1 Finished
-
COBRE: Center of Research in Obesity and Cardiovascular Disease - COBRE Core A: Administrative
Cassis, L. (PI), Abdel-Latif, A. (CoI), Charnigo, R. (CoI), Daugherty, A. (CoI), Graf, G. (CoI), Katz, W. (CoI), Kern, P. (CoI), Morris, A. (CoI), Pearson, K. (CoI), Powell, D. (CoI), Randall, D. (CoI), Smyth, S. (CoI), Subramanian, V. (CoI), Tannock, L. (CoI), Van Der Westhuyzen, D. (CoI), Vandsburger, M. (CoI), Wang, S. (CoI), Webb, N. (CoI), Yiannikouris, F. (CoI) & Hanaoka, B. (Former CoI)
National Institute of General Medical Sciences
9/8/08 → 7/31/16
Project: Research project